294 related articles for article (PubMed ID: 36273512)
1. Biophysical heterogeneity of myeloid-derived microenvironment to regulate resistance to cancer immunotherapy.
Zhao J; Dong Y; Zhang Y; Wang J; Wang Z
Adv Drug Deliv Rev; 2022 Dec; 191():114585. PubMed ID: 36273512
[TBL] [Abstract][Full Text] [Related]
2. Heterogeneous Myeloid Cells in Tumors.
Dou A; Fang J
Cancers (Basel); 2021 Jul; 13(15):. PubMed ID: 34359674
[TBL] [Abstract][Full Text] [Related]
3. Targeting tumour-reprogrammed myeloid cells: the new battleground in cancer immunotherapy.
De Sanctis F; Adamo A; Canè S; Ugel S
Semin Immunopathol; 2023 Mar; 45(2):163-186. PubMed ID: 36161514
[TBL] [Abstract][Full Text] [Related]
4. Shaping the immune-suppressive microenvironment on tumor-associated myeloid cells through tumor-derived exosomes.
Wang H; Liu S; Zhan J; Liang Y; Zeng X
Int J Cancer; 2024 Jun; 154(12):2031-2042. PubMed ID: 38500385
[TBL] [Abstract][Full Text] [Related]
5. Emerging strategies in targeting tumor-resident myeloid cells for cancer immunotherapy.
Wang Y; Johnson KCC; Gatti-Mays ME; Li Z
J Hematol Oncol; 2022 Aug; 15(1):118. PubMed ID: 36031601
[TBL] [Abstract][Full Text] [Related]
6. Tumor-associated myeloid cells in cancer immunotherapy.
Cheng X; Wang H; Wang Z; Zhu B; Long H
J Hematol Oncol; 2023 Jul; 16(1):71. PubMed ID: 37415162
[TBL] [Abstract][Full Text] [Related]
7. Nanomedicine Targeting Myeloid-Derived Suppressor Cells Enhances Anti-Tumor Immunity.
Yang EL; Sun ZJ
Adv Healthc Mater; 2024 Apr; 13(9):e2303294. PubMed ID: 38288864
[TBL] [Abstract][Full Text] [Related]
8. Targeting the myeloid microenvironment in neuroblastoma.
Stip MC; Teeuwen L; Dierselhuis MP; Leusen JHW; Krijgsman D
J Exp Clin Cancer Res; 2023 Dec; 42(1):337. PubMed ID: 38087370
[TBL] [Abstract][Full Text] [Related]
9. Role of Tumor-Associated Myeloid Cells in Breast Cancer.
Cha YJ; Koo JS
Cells; 2020 Jul; 9(8):. PubMed ID: 32726950
[TBL] [Abstract][Full Text] [Related]
10. The New Era of Cancer Immunotherapy: Targeting Myeloid-Derived Suppressor Cells to Overcome Immune Evasion.
De Cicco P; Ercolano G; Ianaro A
Front Immunol; 2020; 11():1680. PubMed ID: 32849585
[TBL] [Abstract][Full Text] [Related]
11. CD200-CD200R Pathway in the Regulation of Tumor Immune Microenvironment and Immunotherapy.
Liu JQ; Hu A; Zhu J; Yu J; Talebian F; Bai XF
Adv Exp Med Biol; 2020; 1223():155-165. PubMed ID: 32030689
[TBL] [Abstract][Full Text] [Related]
12. Myeloid-Derived Suppressor Cells as a Therapeutic Target for Cancer.
Law AMK; Valdes-Mora F; Gallego-Ortega D
Cells; 2020 Feb; 9(3):. PubMed ID: 32121014
[TBL] [Abstract][Full Text] [Related]
13. Tumor-associated myeloid cells: new understandings on their metabolic regulation and their influence in cancer immunotherapy.
Porta C; Sica A; Riboldi E
FEBS J; 2018 Feb; 285(4):717-733. PubMed ID: 28985035
[TBL] [Abstract][Full Text] [Related]
14. Myeloid-derived suppressor cells: an emerging target for anticancer immunotherapy.
Wu Y; Yi M; Niu M; Mei Q; Wu K
Mol Cancer; 2022 Sep; 21(1):184. PubMed ID: 36163047
[TBL] [Abstract][Full Text] [Related]
15. Diamonds in the Rough: Harnessing Tumor-Associated Myeloid Cells for Cancer Therapy.
Clappaert EJ; Murgaski A; Van Damme H; Kiss M; Laoui D
Front Immunol; 2018; 9():2250. PubMed ID: 30349530
[TBL] [Abstract][Full Text] [Related]
16. Myeloid-derived suppressor cells in cancer and cancer therapy.
Lasser SA; Ozbay Kurt FG; Arkhypov I; Utikal J; Umansky V
Nat Rev Clin Oncol; 2024 Feb; 21(2):147-164. PubMed ID: 38191922
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic targeting of tumour myeloid cells.
Barry ST; Gabrilovich DI; Sansom OJ; Campbell AD; Morton JP
Nat Rev Cancer; 2023 Apr; 23(4):216-237. PubMed ID: 36747021
[TBL] [Abstract][Full Text] [Related]
18. Immunosuppressive cells and tumour microenvironment: focus on mesenchymal stem cells and myeloid derived suppressor cells.
Bianchi G; Borgonovo G; Pistoia V; Raffaghello L
Histol Histopathol; 2011 Jul; 26(7):941-51. PubMed ID: 21630223
[TBL] [Abstract][Full Text] [Related]
19. Preclinical ImmunoPET Imaging of Glioblastoma-Infiltrating Myeloid Cells Using Zirconium-89 Labeled Anti-CD11b Antibody.
Nigam S; McCarl L; Kumar R; Edinger RS; Kurland BF; Anderson CJ; Panigrahy A; Kohanbash G; Edwards WB
Mol Imaging Biol; 2020 Jun; 22(3):685-694. PubMed ID: 31529407
[TBL] [Abstract][Full Text] [Related]
20. Potential therapeutic targets in myeloid cell therapy for overcoming chemoresistance and immune suppression in gastrointestinal tumors.
Fan J; Zhu J; Zhu H; Xu H
Crit Rev Oncol Hematol; 2024 Jun; 198():104362. PubMed ID: 38614267
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
